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ABSTRACT We describe a general way of introducing
transgenes into the mouse germ line for comparing different
sequences without the complications of variation in copy
nuniber and insertion site. The method uses homologous
recombination in embryonic stem (ES) cells to generate mice
having a single copy of a transgene integrated into a chosen
location in the genome. To test the method, a single copy
murine bcl-2 cDNA driven by either a chicken 8-actin pro-
moter or a human 18-actin promoter has been inserted imme-
diately 5' to the X-linked hypoxanthine phosphoribosyltrans-
ferase locus by a directly selectable homologous recombina-
tion event. The level of expression of the targeted bcl-2
transgene in ES cells is identical in independently isolated
homologous recombinants having the same promoter yet
varies between the different promoters. In contrast, the
expression of bcl-2 transgenes having the same (chicken
,B-actin) promoter varies drastically when they are indepen-
dently integrated at random insertion sites. Both promoters
direct broad expression of the single-copy transgene in mice
derived from the respective targeted ES cells. In vitro and in
vivo, the human f8-actin promoter consistently directed a
higher level of transgene expression than the chicken f8-actin
promoter.
The generation of transgenic mice by the injection ofDNA into
the male pronucleus of one-cell murine embryos has proven to
be an effective method of achieving expression of exogenous
DNA sequences for many purposes, including overexpression,
ectopic expression, mutant analysis, promoter analysis, deliv-
ery of toxins, and dominant/negative mutations (for review,
see ref. 1). However, DNA incorporated into the mouse germ
line using this method is integrated randomly and in unpre-
dictable copy numbers. The integration site often has a
profound effect on expression of the transgene. Furthermore,
insertion of the transgene in or near another gene, particularly
when the transgene insertion is made homozygous by breeding,
can cause an undesired phenotype (2). Thus, it is estimated
that 5-10% of transgene integration events result in a mutant
phenotype as a consequence of disruptions, deletions, or
translocations (1, 3, 4).
Targeting a single copy of a transgenic sequence to a chosen
location in the genome would have many advantages: the
ability to control copy number, the ability to insert the
transgene into regions of chromatin compatible with a desired
developmental and tissue-specific expression, and the exclu-
sion of insertional mutagenesis as a contributor to the phe-
notype. Targeted transgenes should therefore provide a more
efficient and informative means of securing and comparing the
expression of various transgenic sequences than is available
with current transgenic procedures.
Homologous recombination can, in principle, be used to
target a transgene to any chosen locus in the genome. Con-
sequently, by using homologous recombination in murine
embryonic stem (ES) cells to integrate transgenic sequences
into the genome at a chosen location followed by blastocyst
injection of the modified cells, single-copy chosen-site trans-
genic mouse lines can be obtained. To test this rationale, we
have introduced a transgene linked to two different promoters
into the ubiquitously expressed murine hypoxanthine phos-
phoribosyltransferase (Hprt) locus. We made this choice be-
cause the Hprt gene is a housekeeping gene (5), so that any
promoter inserted into the locus is not likely to be restricted in
its expression by unfavorable chromatin configurations, and
because of the availability of a targeting vector capable of
mediating a highly efficient, directly selectable homologous
recombination event at the Hprt locus (6).
MATERIALS AND METHODS
Targeting Vectors and Constructs. The targeting vector,
pMP8SKB (Fig. 1A), is a modification of pMP8 (6), made by
removing an EcoRI site in the 3' homology region and a NotI
site in the polylinker of the pBLUESCRIPT (Stratagene)
backbone. To provide a "cassetting" site in the vector, a short
linker containing a NotI site and an MluI site was inserted into
the remaining EcoRI site at the downstream end of the 5'
homology while preserving the EcoRI site. The transgenes
were incorporated in the pMP8SKB targeting vector in the
same transcriptional orientation as the downstream Hprt gene.
Two targeting constructs were made using the pMP8SKB
vector. The pCBP8 targeting construct contained a 1640-bp
transgenic cassette (upper line, Fig. 1B), including a 350-bp
region of the chicken f3-actin promoter (7) (a gift from S.
Steven Potter, University of Cincinnati College of Medicine),
an 850-bp murine bcl-2 cDNA (a gift from Stanley Korsmeyer,
Washington University School of Medicine) (8), and an
-440-bp polyadenylylation signal sequence from the phospho-
glycerate kinase (PGK) gene ofpPNT (9) (a gift from Richard
Mulligan, Massachusetts Institute of Technology). The pHBP8
targeting construct contained a 5.8-kb transgenic cassette
(lower line, Fig. 1B), including a 4.5-kb region of the human
f3-actin promoter [taken from pH,BApr-1 (10)], the murine
bcl-2 cDNA, and the PGK polyadenylylation signal sequence.
The pCBP8 targeting construct was electroporated into cells as
a circular plasmid; the pHBP8 targeting construct was linear-
ized with PvuI before electroporation.
pCBPN Construct for Random Integration. The pCBPN
construct (Fig. 1C) used the same transgenic cassette as
pCBP8 except that a copy of the neomycin resistance gene
from pPNT flanked by the PGK promoter and polyadenyly-
lation signal sequences was inserted downstream of the PGK
polyadenylylation signal sequences used for the bcl-2 cDNA.
pCBPN was linearized with PvuI before transfection.
Abbreviations: ES, embryonic stem; B6, C57BL/6J; 129, 129/Ola;
HAT, hypoxanthine/aminopterin/thymidine; Hprt, hypoxanthine
phosphoribosyltransferase (locus).
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ES cells and genotyping of weanling pups were done by
Southern analysis. Hybridization was to a 150-bp fragment
from intron 3 of the murine Hprt gene or to the 850-bp murine
bcl-2 cDNA (8).
mRNA Analysis of Transgenic Animals and ES Cell Lines.
Total cellular RNA was prepared from ES cell lines or fresh
tissues using Tri Reagent (Molecular Research Center, Cin-
cinnati) according to the manufacturer's protocol. Fifteen
micrograms of RNA was electrophoresed on a 17.5% form-
aldehyde/1% agarose gel and transferred to nylon membrane
as described (12). The Hprt probe was a 300-bp XhoI/HindIII
fragment from pNIlAc,2 (13). The human f3-actin cDNA was
from Clontech.
bcl-2










FIG. 1. DNA vectors, cassettes, and constructs. (A) The pMP8SKB
vector. Regions corresponding to 5' and 3' homology sequences are
indicated by 5'H and 3'H, exons are represented by heavy vertical lines,
and plasmid sequences are represented by a solid curved line. Pv, PvuI;
E, EcoRI; N, NotI; and M, MluI. (B and C) The transgenic cassettes
(B) and the random integration construct (C). The chicken 13-actin
promoter and the human ,B-actin promoter are depicted by labeled
diagonal striped boxes; the bcl-2 cDNA is depicted by labeled black
boxes; sequences containing polyadenylylation signals are depicted by
the labeled open boxes; pgk-neoR represents a neomycin resistance
gene flanked by the PGK promoter and poly(A) addition sequences.
Cell Lines and Culture. The ES cell line used in this work
(BK4) was a gift from Beverly Koller (University of North
Carolina, Chapel Hill); it is a subclone of E14TG2a (11). The
E14 parent cell line was derived from a 129/Ola (129) strain
mouse. ES cells were grown on murine embryonic fibroblasts
in DMEM-H (Life Technologies, Gaithersburg, MD) supple-
mented with 15% fetal bovine serum (Life Technologies), 0.1
mM 2-mercaptoethanol, and 2 mM L-glutamine. For the gene
targeting experiments, -2 x 107 cells were electroporated with
3 nM of the targeting DNA ('0.015 mg) in 0.5 ml of medium
at 400 V and 50 ,uF for 1 sec. Homologous recombinants were
selected in HAT medium (0.016 mg of hypoxanthine per
ml/0.01 mM aminopterin/0.0048 mg of thymidine per ml) for
"10 days, at which time individual colonies were picked for
expansion and verification of the desired recombination by
Southern analysis. The frequency of HAT-resistant colonies
per cells electroporated ranged from 1 X 10-5 to 1 X 10-6, with
the linearized plasmids yielding "10 times more colonies than
circularized plasmids. For the random integration experi-
ments, ES cells and linearized pCBPN DNA were incubated
with a calcium phosphate precipitate as described (12). Trans-
fected cells were selected in the above ES cell growth medium
supplemented with 0.2 mg of G418 sulfate per ml (Life
Technologies). Approximately 1 in 105 transfected cells were
G418 resistant.
Generation of ES Cell-Derived Mice. Targeted strain 129-
derived ES cells were injected into the blastocoele of
C57BL/6J (B6) blastocysts, and the blastocysts were surgically
transferred to the uteri of pseudopregnant CD1 females
(Charles River Breeding Laboratories). Resulting chimeras
were bred with B6 mice (The Jackson Laboratory) to give wild
type and transgenic 129/B6 Fl pups.
Detection of the Targeted Locus by Southern Analysis.
Verification of the homologous recombination events in the
RESULTS
Integration of Transgenes by Homologous Recombination.
To test the single-copy chosen-site method for generating
transgenic mice, two different promoters were linked to the
murine bcl-2 cDNA and introduced into the mouse genome
immediately upstream of the Hprt gene using homologous
recombination in ES cells (Fig. 2). One of the promoters was
from the chicken f3-actin gene; the other was from the human
13-actin gene. The ES cell line used was the 6-thioguanine
resistant line E14TG2a derived from the 129 ES cell line E14
(11). This ES cell line is karyotypically male, and thus hem-
izygous for the X chromosome-linked Hprt locus. The se-
quences flanking the deletion that makes the E14TG2a ES cell
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FIG. 2. Strategy for generating a targeted transgene at the deleted
Hprt locus of the E14TG2a cell line.A-C illustrate a replacement event
mediated by two crossovers (X and X), and D-F illustrate an insertion
event mediated by a single crossover (X). A and D are a schematic
representation of the endogenous E14TG2a Hprt locus, B and E show
targeting constructs, and C and F show the resulting targeted loci
modified by homologous recombination restoring Hprt function and
introducing the transgenic sequences. The genomic locus is repre-
sented by an unshaded box, exons are numbered, the brackets mark the
deletion, and the wavy vertical lines indicate continuity with the
chromosome. The DNA of the targeting construct is represented by a
shaded box, P and 1 represent the human promoter and human exon
1 sequences, and Tg represents transgenic sequences. Plasmid se-
quences are represented by a thin solid line.
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FIG. 3. Northern analysis ofRNA from targeted ES cell lines. Blots
were hybridized first with a murine bcl-2 cDNA (Upper) and then with
a human ,B-actin cDNA (Lower). Samples 2A, 2B, 9A, 9B, and 9C
contain total RNA from ES cells targeted by pCBP8 (chicken ,B-actin
promoter). Samples 6B, 8A, 8B, 8C, and 8D are total RNA from ES
cells targeted by pHBP8 (human 13-actin promoter). The ES cell clone
2B was the product of an insertional recombination event (Fig. 2C).
The other clones were products of replacement recombination event
(Fig. 2F). Exposure times were 5 days (bcl-2) and 5 h (actin).
line 6-thioguanine resistant are well characterized and have
been used to create a locus-specific targeting vector, pMP8 (6).
The targeting vector pMP8 includes sequences capable of
restoring a functional Hprt gene following recombination so
that homologous recombinants can be directly selected for in
HAT medium. We modified pMP8 to give pMP8SKB, which
is arranged to allow easy insertion of transgenic cassettes
between the 5' homology sequences and the Hprt gene se-
quences (Fig. 1A). The resulting targeting constructs were
used for recombination-mediated introduction of a single copy
of the transgenic sequences into the chosen site in the genome
immediately upstream of a functional Hprt gene.
The targeting construct with the chicken 13-actin promoter
was electroporated as a circular plasmid, a configuration
favoring an insertional recombination event (see Fig. 2 E and
F). The targeting construct with the human f3-actin promoter
was linearized before electroporation, a configuration favoring
a replacement event (see Fig. 2 B and C). Although these two
mechanisms modify the locus in different ways, both result in
complementation of the Hprt deletion and insertion of a
single-copy of a transgenic cassette upstream of the Hprt gene
sequences. Sequences downstream of the transgenes and up to
4 kb upstream of the transgenes are identical after both types
of recombination event (Fig. 2 C and F).
< WU U_ (9
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Transgene Expression in ES Cells. Northern analysis was
used to determine the expression of the targeted transgenes in
ES cell lines. Fig. 3 is a Northern blot of total RNA from ES
cell lines containing five independently targeted bcl-2 trans-
genes with the chicken j3-actin promoter (2A, 2B, 9A, 9B, and
9C) and five independently targeted bcl-2 transgenes with the
human f3-actin promoter (6B, 8A, 8B, 8C, and 8D). The
transgenic mRNAs were readily detected and were of the
expected length, 1.1 kb. In all, a total of 15 independently
derived clones of pCBP8 (chicken actin promoter) targeting
were tested, and all had identical RNA expression levels in ES
cells. The same was true for five independently derived clones
of pHBP8 (human actin promoter) targeting. In addition, we
detected no difference in the level of expression from targeted
transgenes resulting from the two types of recombination event
(compare 2B to 2A, 9A, 9B, 9C in Fig. 3). Thus independent
targeting events involving either of the two transgenic cassettes
result in identical expression in ES cells. Yet the unique
characteristics of each transgene are readily detected, as
illustrated in Fig. 3 which shows that expression of the bcl-2
transgene driven by from the chicken 63-actin promoter is
consistently lower than expression of the bcl-2 transgene driven
by the human ,B-actin promoter.
To directly compare the expression of a targeted transgene
to that of the same transgene randomly integrated into the
genome, the chicken ,B-actin promoter-containing transgene
cassette was introduced into a vector that includes a neomycin
resistance gene. The resulting construct, pCBPN (Fig. 1C) was
then transfected into ES cells. Twenty-seven G418 resistant ES
cell lines were generated. Fig. 4 is a northern blot of total RNA
which compares expression from the two types of targeted
transgene (2A having the chicken actin promoter and 8C
having the human actin promoter) to that of 12 replicates of
the randomly integrated chicken ,B-actin promoter transgene
(A, E, F, G, H, J, K, N, P, T, V, W). Expression in the clones
with randomly integrated transgenes was extremely variable,
ranging from well below (E and W) the level of the targeted
chicken promoter-driven targeted transgene (2A) to well
above (T) the level of the human promoter-driven transgene
(8C). (mRNA from the endogenous bcl-2 gene is greater than
7.5 kb in size because of a long 3' untranslated region. Due to
the difficulty of preserving an mRNA of this length, the
intensity of the endogenous band is not a reliable index of the
amount of total RNA loaded per lane.) In all we tested 27 ES
cell lines with randomly integrated constructs; of these 5 had
high level expression of the bcl-2 transgene (illustrated by lanes







FIG. 4. Northern analysis of RNA from ES cell lines. Lettered samples contain total RNA from ES cells lines having randomly integrated
transgenes. 2A and 8C are targeted ES cell lines described in the legend to Fig. 3. The sizes (in kilobases) of marker fragments are indicated. Exposure
times were 5 days (bcl-2) and 12 h (actin).
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K, P and T), 9 had intermediate level expression (illustrated by
lanes J and V), and 13 had low level expression (illustrated by
lanes A, E, F, G, H, N, and W). No correlation was observed
between the level of expression and the number of copies of the
transgene, as determined by Southern hybridization (data not
shown). Thus, as has been reported by many previous inves-
tigators, the expression of the randomly integrated transgene
varies drastically from replicate to replicate (Fig. 4) and is not
directly related to copy number. In contrast, expression of
replicates of each of the targeted transgenes are essentially
invariant (Fig. 3).
Generation of Transgenic Animals. To test the targeted
transgenes in the whole animal, correctly targeted ES cells
were injected into 3.5-day blastocyst-stage B6 embryos. The
resultant male chimeras were bred to B6 females. Agouti pups
from these crosses are 129/B6 F1 hybrids that have received
the 129 ES cell genome. Because the Hprt gene is X-linked, all
the female agouti mice are heterozygous for the targeted
transgene but none of the agouti males are transgenic. The
transgenic females can be used to generate hemizygous trans-
genic males, and interbreeding the transgenic males and
females can then generate homozygous females.
Southern analysis demonstrated that the transgenic lines
created by our targeting scheme have as expected, single-copy
single-site transgenes. For this analysis, genomic DNA was
digested with BamHI and hybridized with probes specific for
either intron 3 of the Hprt locus (Fig. 5 Upper) or for bcl-2 (Fig.
S Lower). The Hprt probe detects a 7-kb fragment in wild-type
females and males and in the heterozygous females from the
targeted lines; this fragment is from the wild-type Hprt locus
on the strain B6-derived X chromosome. A fragment of 8.5 kb
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FIG. 5. Southern analysis of wild-type and transgenic animals. All
lanes contain BamHI-digested genomic male (M) or female (F) DNA
hybridized with a probe from the murine Hprt locus (Upper) or the
bcl-2 cDNA (Lower). cba-mbcl-2 and hba-mbcl-2 indicate animals
generated from pCBP8 or pHBP8 targeted ES cells. hom and het,
Homozygous or heterozygous animals, respectively. The sizes (in
kilobases) of marker fragments are indicated.
is detected in animals from the two targeted transgenic lines;
this fragment corresponds to the transgenic X chromosome
modified by homologous recombination with the two targeting
constructs. (The 12.5-kb hybridizing fragment in DNA from
the chicken 13-actin promoter line is from the upstream du-
plication of the 3' homology region generated during insertion-
type replacement; see Fig. 2F.) Homozygous females and
hemizygous males show only hybridizing fragments derived
from the targeted Hprt locus.
The murine bcl-2 cDNA (Fig. 5 Lower) detects 1.5- and
12-kb fragments derived from the endogenous bcl-2 locus. The
5-kb and 9-kb fragments are from the targeted transgenes
having the chicken actin and the human actin promoter,
respectively. In every case, the hybridizing bands are of the
predicted size for targeted events.
Expression of the Single-Copy bcl-2 Transgene in the
Mouse. We compared the in vivo transcriptional activities of
the two promoters adjacent to the reconstituted Hprt locus. As
shown in Fig. 6 A and B (Top), the chicken and human actin
promoters both direct transgene expression in a wide variety
of tissues, including bone marrow, brain, heart, thymus, kidney,
spleen, and reproductive organs. Expression of the targeted
transgene with the human f3-actin promoter is much higher
than expression of the targeted transgene with the chicken
,B-actin promoter in all tissues, although less obvious in the
hba-mbcl-2 bone marrow because of some degradation of the
RNA. (Hybridization of the blots with a human ,-actin cDNA,
Fig. 6 Bottom, provides a measure of amounts ofRNA loaded.)
Sequential hybridization of the Northern blots used to
prepare the top panels of Fig. 6 with a probe from the Hprt
locus (Fig. 6A and B, Middle) revealed two points of interest.
First, expression of the Hprt gene is greater when it is adjacent
to the human f3-actin promoter than when next to the chicken
f3-actin promoter. [Control heterozygous animals having a
targeted Hprt locus with a nontranscribed transgene have Hprt
expression similar to the transgenes with the chicken ,B-actin
promoter (data not shown).] Second, the Hprt gene appears to
be expressed in all tissues including the liver and kidney, two
tissues with low or undetectable transgene expression.
As with many X-linked loci, the Hprt gene is transcription-
ally silent on the inactivated X chromosome in females (14-
16). Consequently, in heterozygous females random inactiva-
tion of the transgene should occur early in development,
although differential survival of the resulting cells might later
skew the final cell population in either direction depending on
whether the transgene is detrimental or beneficial. Northern
analysis of transgene expression in heterozygous females,
homozygous females, and hemizygous males suggests that the
transgenes are randomly inactivated in females since homozy-
gous females and hemizygous males have similar levels of
transgene expression (data not shown). (If the transgenes did
not undergo random inactivation, homozygous females would
be expected to have two transcriptionally active transgenes and
thus twice as much transgenic mRNA as a hemizygous male.)
Given random inactivation in females, heterozygous females
would be expected to have half the transgene expression of
homozygous females. Yet, in the heterozygous and homozy-
gous females with targeted bcl-2 transgenes, the relative levels
of transgene expression vary from tissue to tissue, indicating
differential survival of cells with active transgenic X chromo-
somes (data not shown).
DISCUSSION
We have described a method that uses homologous recombi-
nation in murine ES cells to generate mice having a single-copy
of a transgene inserted at a chosen site in the genome. The
method has been tested by inserting the murine bcl-2 gene with
two different promoters (chicken ,B-actin and human ,B-actin)
into the mouse genome adjacent to the Hprt locus in ES cells.
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FIG. 6. Northern analysis of RNA from transgenic mouse tissues. Animals from the cba-bcl-2 and hba-bcl-2 lines were 1- to 2-month old
heterozygous females. The Top, Middle, and Bottom panels are the same northern blot hybridized to a murine bcl-2 cDNA, a human Hprt cDNA,
or a human ,-actin cDNA. The exposure times for the three hybridizations are 72, 24, and 6 h, and the actin exposure was without intensifying
screens. The sizes (in kilobases) of marker fragments are indicated.
For comparison, we generated transgenic ES cell lines con-
ventionally through random integration of a chicken f3-actin-
driven bcl-2 gene. Our first expectation was that transgenes
resulting from independently replicated targeting events me-
diated by a given construct would direct identical transgene
expression in ES cells, while independent replicates of ran-
domly integrated transgenes would direct varied transgene
expression in ES cells. This expectation was fully confirmed.
ES cells having the targeted transgenes driven by the two
promoters were used to establish transgenic mouse lines, and
the in vivo expression of the transgenes was investigated. It is
well known that expression of a transgene in part reflects the
general features of the chromosomal region into which it is
inserted. The Hprt gene is expressed ubiquitously, presumably
because it is in a permissive chromosomal domain, and the
endogenous f3-actin promoter directs ubiquitous expression at
its natural locus. Thus, our second expectation was that, in
animals having targeted transgenes with 3-actin promoters
inserted close to the Hprt locus, expression of the transgenes
would be found in wide variety of tissues. This second expec-
tation was also confirmed in that we were able to show that
both of these promoters, when close to the Hprt locus, direct
expression at moderate levels in a wide variety of tissues, in a
manner that closely resembles the expression pattern of the
endogenous j3-actin gene. In two of the tissues analyzed,
kidney and liver, transgene expression was low or undetect-
able. This lack of expression could be due to the particular
promoter fragments or to the polyadenylylation signal se-
quences; but it is unlikely to be due to restrictive chromatin at
the target locus because expression of the Hprt gene is easily
detectable in these tissues.
Expression in ES cells of the targeted transgene driven by
the chicken ,B-actin promoter was the same regardless of the
type of recombination used to modify the locus and was
significantly less in comparison to targeted transgene expres-
sion from the human f3-actin promoter in ES cells. We also
observed that the human ,B-actin driven bcl-2 transgene was
consistently expressed in the transgenic animal at a higher level
than the chicken ,B-actin driven transgene in all tissues, al-
though the two sets of transgenic animals were derived from
targeted ES cell lines having undergone different types of
recombination events. These consistent differences between
the two promoters provides a strong case for suggesting that
the expression of the two transgenes reflects real differences
between the two promoters-presumably because of the pres-
ence of an intron in the human but not in the chicken /3-actin
promoter. In general, targeting single copies of transgenes with
different promoters to the same site in the genome allows a
quantitative comparison between two promoters that is essen-
tially impossible in the living animal using conventional trans-
genic methods, which lead to random integrations of varying
numbers of the transgenic sequences.
Shaw-White et al. (17), have described experiments in ES
cells in which a lacZ transgene with a herpes simplex virus-
thymidine kinase (HSV-TK) promoter was inserted into the
Hprt gene in- a manner that disrupts the Hprt gene; they
observed inconsistent and low level expression of the lacZ
transgene, which they interpreted as being due to competition
between transcripts of the interrupted Hprt gene and the lacZ
transgene. Our experiments demonstrate that insertion of
transgenes upstream of a functional Hprt gene leads to con-
sistent transgene expression in the expected tissues. The
reason for these differences is not clear but could be due to the
location of the transgene in the locus.
The method that we have developed should be generally
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choose the acceptor locus for the targeted transgene based on
the tissue specificity of expression at that locus-e.g., the
erythroid specificity of the ,3-globin locus (18)-or the liver
specificity of the apolipoprotein Al/Clll locus (19). Such
choices would be expected to lead to useful interactions
between the transgenes and regulatory elements at the target
locus. Targeted transgenes inserted at a locus other than the
Hprt locus will not usually be directly selectable. However,
several methods have been described recently that enable the
use of selection for repeated targeting of any locus (20-23).
One of the methods, the plug and socket method, employs
direct selection for Hprt function so that its adaptation for use
in making chosen-site transgenes would retain the convenience
we obtained here from use of the deleted Hprt locus in
E14TG2a cells (21).
The E14TG2a Hprt locus is, however, particularly useful for
studying single-copy chosen-site transgenes for several rea-
sons. First, the locus is directly selectable, so that the gene
targeting experiment is no more difficult than a simple trans-
fection experiment. Second, the Hprt gene is expressed in
essentially all tissues and at virtually all developmental stages,
indicating that it lies in a constitutively open chromatin region;
accordingly, tissue and developmentally specific promoters
and enhancers can be expected to retain their natural speci-
ficity when used to drive the targeted transgene. Third, the
X-chromosomal location of the Hprt locus, coupled with the
random inactivation of transgenes in heterozygous females but
not in homozygous females or hemizygous males, provides an
interesting way of determining the effects of the transgene in
various tissues. It could even allow the generation of transgenic
animals through the mosaic expression of a transgene that
would be lethal when expressed in all tissues.
We suggest that our method of generating targeted trans-
genes will be generally useful and should facilitate the study of
regulatory sequences in vivo and the development of mutant
promoters having precise quantitative effects. Finally, we
emphasize that the use of a chosen site for a single copy of a
transgene avoids many of the problems associated with ran-
domly inserted transgenes.
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